Cymab ApS: Financial statements 2020
CVR: 39859173
Source: annual report 2020, Danish Business Authority
01/01/2020 – 31/12/2020
Cymab ApS (CVR 39859173) has filed annual accounts for 2020. In 2020, the company reported a gross profit of DKK -1,077,255 and a net result of DKK -955,753. Equity in the 2020 report amounted to DKK -2,959,262.
- Revenue
- DKK 0
- Gross Profit
- DKK -1,077,255
- Profit/Loss
- DKK -955,753
- Equity
- DKK -2,959,262
- Total Assets
- DKK 342,646
Official annual report
How creditworthy is Cymab ApS?
See the CDS score and get a full credit report with recommended credit limit and payment terms.
Read about the CDS scoreEvents in 2020
Cymab ApS has published its interim report for the period September 10, 2018 to December 31, 2019.
As of July 15, 2020, Slotsgade Revision ApS has been appointed auditor of Cymab ApS.
As of July 15, 2020, KAPPELSKOV REVISION. GODKENDT REVISIONSAKTIESELSKAB has stepped down as auditor of Cymab ApS.
As of June 22, 2020, Hans Heugh Wandall has joined the board of directors of Cymab ApS.
As of June 22, 2020, Søren Erik Bjørn has joined the board of directors of Cymab ApS.
As of June 22, 2020, Kim Stengaard Holmsted has left the board of directors of Cymab ApS.
As of June 21, 2020, Hans Heugh Wandall has left the board of directors of Cymab ApS.
About Cymab ApS
Cymab ApS is a Danish company of the type Anpartsselskab based in København N, founded in 2018. The company is registered under the industry Fremstilling af farmaceutiske præparater. The company was previously named Ebumab ApS. The management consists of Johan Henrik Faber. The board consists of Hans Heugh Wandall (chair), Johan Henrik Faber, Mads Nikolaj Behrndt-Eriksen and Søren Erik Bjørn. The company is owned by Ebumab Holding ApS. The company has 2 employees (2026). In 2025, the company reported a gross profit of DKK -5,463,240 and a net result of DKK -7,576,022 compared with DKK -4,627,624 the year before. Equity in the 2025 report amounted to DKK -20,227,476.